NEW YORK, Jan. 28, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for AMAG Pharmaceuticals, Inc. shareholders (NASDAQ:AMAG). Concerned AMAG investors who purchased between December 24, 2012 and January 8, 2015 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
The law firm's investigation will focus on potential violations of the federal securities law. AMAG proposed to the U.S. Food and Drug Administration ("FDA"), on June 2, 2014, changes to the current U.S. label of Feraheme Injection based on a review of global post-marketing data. The proposed label changes in the U.S. were to enhance patient safety by strengthening the warnings and precautions section of the label, and mitigate the risk of serious hypersensitivity reactions, including anaphylaxis. The proposed changes were subject to review and approval by the FDA. On January 7, 2015, after considering AMAG's June 2014 submission and other information, the FDA notified AMAG that it believes new safety information should be included in the labeling of Feraheme, including, among other things, a boxed warning to highlight the risks of serious hypersensitivity/anaphylaxis reactions and revisions that Feraheme should only be administered through an intravenous ("IV") infusion, (i.e., not by IV injection), and should be contraindicated for patients with any known history of drug allergy. The FDA's recommended label changes go beyond what AMAG proposed in June 2014. On this news, AMAG's shares are down $2.65 (5.67%), currently trading at $43.33. Our potential shareholder lawsuit will seek to ensure that AMAG Pharmaceuticals, Inc. works to enrich shareholders, not just the management.
Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. AMAG stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/AMAG.
SOURCE Dunnam & Dunnam